HUP9901186A3 - Pharmaceutical composition for immunomodulation based on peptides and adjuvants - Google Patents

Pharmaceutical composition for immunomodulation based on peptides and adjuvants

Info

Publication number
HUP9901186A3
HUP9901186A3 HU9901186A HUP9901186A HUP9901186A3 HU P9901186 A3 HUP9901186 A3 HU P9901186A3 HU 9901186 A HU9901186 A HU 9901186A HU P9901186 A HUP9901186 A HU P9901186A HU P9901186 A3 HUP9901186 A3 HU P9901186A3
Authority
HU
Hungary
Prior art keywords
adjuvants
peptides
pharmaceutical composition
immunomodulation based
immunomodulation
Prior art date
Application number
HU9901186A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901186(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUP9901186A2 publication Critical patent/HUP9901186A2/hu
Publication of HUP9901186A3 publication Critical patent/HUP9901186A3/hu
Publication of HU224410B1 publication Critical patent/HU224410B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
HU9901186A 1996-02-24 1997-02-21 Peptid- és adjuvánsalapú gyógyszerkészítmény immunmodulációra HU224410B1 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (3)

Publication Number Publication Date
HUP9901186A2 HUP9901186A2 (hu) 1999-07-28
HUP9901186A3 true HUP9901186A3 (en) 2001-01-29
HU224410B1 HU224410B1 (hu) 2005-08-29

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901186A HU224410B1 (hu) 1996-02-24 1997-02-21 Peptid- és adjuvánsalapú gyógyszerkészítmény immunmodulációra

Country Status (35)

Country Link
US (1) US7105162B1 (hu)
EP (1) EP0881906B2 (hu)
JP (1) JP4184433B2 (hu)
KR (1) KR100457647B1 (hu)
CN (1) CN1177610C (hu)
AR (1) AR005945A1 (hu)
AT (1) ATE274350T1 (hu)
AU (1) AU722264B2 (hu)
BG (1) BG63682B1 (hu)
BR (1) BR9707694A (hu)
CA (1) CA2243559C (hu)
CO (1) CO4600681A1 (hu)
CZ (1) CZ295396B6 (hu)
DE (1) DE59711873D1 (hu)
DK (1) DK0881906T4 (hu)
EE (1) EE04481B1 (hu)
ES (1) ES2225951T5 (hu)
HK (1) HK1017257A1 (hu)
HR (1) HRP970100B1 (hu)
HU (1) HU224410B1 (hu)
ID (1) ID16038A (hu)
IL (1) IL125361A (hu)
MY (1) MY119276A (hu)
NO (1) NO983850L (hu)
NZ (1) NZ332020A (hu)
PE (1) PE55398A1 (hu)
PL (1) PL189413B1 (hu)
PT (1) PT881906E (hu)
RO (1) RO119344B1 (hu)
RS (1) RS50101B (hu)
SI (1) SI0881906T2 (hu)
SK (1) SK284582B6 (hu)
TR (1) TR199801649T2 (hu)
TW (1) TW585774B (hu)
WO (1) WO1997030721A1 (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69910743T2 (de) * 1998-02-25 2004-07-08 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp-ribosylating-exotoxin induzierten immunantwort
EP1071411B1 (en) * 1998-04-20 2007-03-14 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
CA2362204C (en) * 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
EP1347775B1 (en) * 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
EP2314718A1 (en) 2003-04-15 2011-04-27 Intercell AG S. pneumoniae antigens
CA2522986A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens i + ii
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
EP2275131A3 (en) 2003-07-11 2012-01-25 Intercell AG HCV Vaccines
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE602005020815D1 (de) 2004-09-24 2010-06-02 Intercell Ag Verändertes vp-1capsidprotein von parvovirus b19
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
US8236326B2 (en) 2007-05-02 2012-08-07 Intercell Ag Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
JP2010530229A (ja) 2007-06-18 2010-09-09 インターセル アーゲー クラミジア属の抗原
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
EP2257287B1 (en) * 2008-03-27 2018-10-10 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
CA2745205A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl trna synthetase (gts) fragments
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
CN102740882A (zh) * 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELS BASED ON POLYSACCHARIDE
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
EP3431595A4 (en) * 2016-03-15 2019-11-20 Repertoire Genesis Incorporation MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
MX2018014602A (es) * 2016-05-27 2019-06-10 Etubics Corp Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (hu) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) * 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London, Gb Peptidfragmente von hiv.
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
CA2072351A1 (en) 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ5191U1 (cs) * 1993-07-12 1996-09-12 Aliatros Medical, A.S. Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
PL328455A1 (en) 1999-02-01
AU1875997A (en) 1997-09-10
YU6297A (sh) 1999-09-27
RO119344B1 (ro) 2004-08-30
CZ295396B6 (cs) 2005-08-17
SK114598A3 (en) 1999-06-11
CZ268998A3 (cs) 1999-07-14
DK0881906T3 (da) 2004-12-20
EE04481B1 (et) 2005-06-15
NZ332020A (en) 2000-02-28
SI0881906T1 (en) 2004-12-31
CA2243559C (en) 2011-08-09
BG63682B1 (bg) 2002-09-30
PE55398A1 (es) 1998-09-22
RS50101B (sr) 2009-01-22
HU224410B1 (hu) 2005-08-29
CN1177610C (zh) 2004-12-01
AR005945A1 (es) 1999-07-21
BR9707694A (pt) 1999-07-27
AU722264B2 (en) 2000-07-27
CA2243559A1 (en) 1997-08-28
NO983850D0 (no) 1998-08-21
EP0881906A1 (de) 1998-12-09
BG102714A (en) 1999-06-30
CN1211926A (zh) 1999-03-24
DK0881906T4 (da) 2009-05-25
CO4600681A1 (es) 1998-05-08
HK1017257A1 (en) 1999-11-19
DE59711873D1 (de) 2004-09-30
ES2225951T3 (es) 2005-03-16
JP4184433B2 (ja) 2008-11-19
IL125361A0 (en) 1999-03-12
EP0881906B1 (de) 2004-08-25
MY119276A (en) 2005-04-30
KR100457647B1 (ko) 2005-06-20
EP0881906B2 (de) 2009-02-04
NO983850L (no) 1998-10-21
WO1997030721A1 (de) 1997-08-28
TR199801649T2 (xx) 1998-12-21
ID16038A (id) 1997-08-28
JP2000506125A (ja) 2000-05-23
IL125361A (en) 2002-08-14
HRP970100B1 (en) 2001-04-30
US7105162B1 (en) 2006-09-12
TW585774B (en) 2004-05-01
SI0881906T2 (sl) 2009-06-30
HRP970100A2 (en) 1998-04-30
HUP9901186A2 (hu) 1999-07-28
PL189413B1 (pl) 2005-08-31
PT881906E (pt) 2004-10-29
ATE274350T1 (de) 2004-09-15
EE9800255A (et) 1999-02-15
KR19990082601A (ko) 1999-11-25
SK284582B6 (sk) 2005-07-01
ES2225951T5 (es) 2009-06-15

Similar Documents

Publication Publication Date Title
IL125361A0 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
IL128529A0 (en) Anti-inflammatory peptides and uses thereof
AUPO066096A0 (en) Oral delivery of peptides
AU6360394A (en) Vasonatrin peptide and analogs thereof
HRP970308B1 (en) Peptide derivatives
AU1731997A (en) Antipathogenic peptides and compositions comprising them
IL114407A0 (en) Novel peptides and pharmaceutical compositions comprising them
ZA97283B (en) Isolated tyrosinase derived peptides and uses thereof
HK1015383A1 (en) Peptide derivatives
IL128556A0 (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
AU3986397A (en) Human glycine transporter
EP0935608A4 (en) CYTOTOXIC PEPTIDES
NZ245239A (en) Hemoregulatory peptides and pharmaceutical compositions
IL116976A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
AU6338698A (en) Tripeptide and tetrapeptide pharmaceutical compounds
IL112094A0 (en) Novel peptides and pharmaceutical compositions comprising them
ZA96741B (en) Peptide a method for its preparation and a pharmaceutical composition containing the peptide
SG54113A1 (en) Novel peptide a method for its preparation and a pharmaceutical composition containing the peptide
IL115518A (en) Peptides and pharmaceutical compositions comprising them
AUPM832694A0 (en) Peptides and polypeptides
SG55039A1 (en) Peptides
GB9626362D0 (en) Peptides
GB9625227D0 (en) Peptides
GB9612648D0 (en) Peptides
GB9608430D0 (en) Peptides

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050712

MM4A Lapse of definitive patent protection due to non-payment of fees